Compare Nerdwallet Inc (NRDS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nerdwallet Inc trades at $9.22 (market cap $603.70M), while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| NRDS | XBI | |
|---|---|---|
Market Cap | $603.70M | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $15.93 | $164.28 |
52-Week Low | $7.58 | $85.16 |
Enterprise Value | $518.00M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRDS trades at $9.12, down 1.51% today, with a bearish technical signal but strong fundamentals including a 93% gross margin and consistent earnings beats. Revenue grew to $836.6M in 2025, with net income reaching $48.7M. Positive analyst sentiment includes a $12.75 consensus target, though technical indicators show near-term pressure.
The stock offers value with a P/E of 9.87 and upside potential from analyst targets, but faces risks from competitive pressures and reliance on consumer financial health. Earnings growth and margin expansion are key catalysts, yet macroeconomic sensitivity could impact performance.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
